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Abstract Quantitative positron emission tomography/
computed tomography (PET/CT) can be used as diagnostic
or prognostic tools (i.e. single measurement) or for therapy
monitoring (i.e. longitudinal studies) in multicentre studies.
Use of quantitative parameters, such as standardized uptake
values (SUVs), metabolic active tumor volumes (MATVs) or
total lesion glycolysis (TLG), in a multicenter setting requires
that these parameters be comparable among patients and sites,
regardless of the PET/CT system used. This review describes
the motivations and the methodologies for quantitative PET/
CT performance harmonization with emphasis on the EANM
Research Ltd. (EARL) Fluorodeoxyglucose (FDG) PET/CT
accreditation program, one of the international harmonization
programs aiming at using FDG PET as a quantitative imaging
biomarker. In addition, future accreditation initiatives will be
discussed. The validation of the EARL accreditation program
to harmonize SUVs and MATVs is described in a wide range
of tumor types, with focus on therapy assessment using either
the European Organization for Research and Treatment of
Cancer (EORTC) criteria or PET Evaluation Response
Criteria in Solid Tumors (PERCIST), as well as liver-based
scales such as the Deauville score. Finally, also presented in
this paper are the results from a survey across 51 EARL-
accredited centers reporting how the program was implement-
ed and its impact on daily routine and in clinical trials, harmo-
nization of new metrics such as MATV and heterogeneity
features.
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Background: The need to harmonize procedures
Metrics frequently used in PET/CT quantification
Quantification of whole body oncology FDG PET/CT
studies is mainly performed using standardized uptake
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values (SUVs). SUVs are computed with the following
equation:
SUV ¼
Activity in tumour Bq
.
cc
 
Injected activity Bqð Þ  weight gð Þ
The activity in the tumor can be derived by using, for ex-
ample, the maximum uptake in the tumor, providing SUVmax,
or by using the average over a region of interest, SUVmean. If
the region of interest is given by a 1 mL sphere positioned to
yield the highest value in the tumor, SUV is referred to as
SUVpeak. The injected activity represents the net administered
FDG activity, corrected for decay and residual activities in the
administration system or syringe. Patient weight is still most
commonly used as the normalization factor in the equation.
However, given that hardly any FDG is taken up by fat and
that antineoplastic treatments can affect the patient’s weight,
the lean body mass (LBM) has been recommended instead of
weight. LBM is usually based on weight and height measure-
ments, though it has been shown that it could be extracted
from the low-dose CT component of the PET/CT acquisition
[1–3]. Further details on LBM evaluation can be found in the
last section of this review, together with other suggested im-
provements in SUV calculations.
Recently there is increasing interest in deriving the
metabolic active tumor volumes (MATVs) and total le-
sion glycolysis (TLG) metrics. MATV can be obtained
by delineating the tumor using, for example, a 41% of
SUVmax isocontour threshold as per EANM guidelines
[4, 5], or by advanced algorithms including information
on gradients or the background surrounding the tumor.
The frequency of MATV usage, irrespective of the
methodology used for tumor contouring, is shown in
Fig. 1.
MATV has gained a lot of interest as a pre-treatment
prognostic tool in various cancer types, but can be ham-
pered by the same errors as for SUVs, with variability
in tumor delineation methodology being one of the ma-
jor sources of variability. Delineation of MATVs is also
useful for radiotherapy planning in various cancers in-
cluding non-small cell lung cancer (NSCLC) [6]. The
impact of PET imaging parameters on automatic tumor
delineation for radiotherapy planning has been well doc-
umented [7–9], prompting the need for an improved and
standardized delineation methodology. Also, though re-
cent studies in non-Hodgkin lymphoma (NHL) have
shown high MATV to be predictive for overall survival
[10], widely disparate cut-off values were found, fuel-
ling the ongoing reflexions on the need to standardize
the quality of PET images and the delineation
methodology.
Fig. 1 shows the frequency of use of the different SUV
metrics and MATVas of December 2016.
SUVand MATV can be used as biomarkers for diagnostic
or prognostic purposes, but their main use is therapy monitor-
ing of antineoplastic treatments. The use of these metrics to
evaluate response to a given treatment is based on the fact that
the observed changes in tumor uptake are greater than that due
to inherent statistical fluctuations. In that setting, recent test-
retest studies have shown repeatability of SUV measurements
better than those published in former generation PETsystems,
including standalone PET. A specific issue is the variability in
SUV calculated by different software packages, as was point-
ed out by, among others, Pierce et al. [11].
Issues related to quantification in PET/MR
In the last five years, cross-modality hybrid PET imaging
combined with MRI has started to enter the clinical arena.
Both sequential [12] and integrated systems [13, 14] are avail-
able using different PET signal detection technologies. MRI
offers superior soft tissue contrast depiction over CT, where
more dense structures like bone are resolved best. For the
quantitative validity of the PET measurements – i.e. the cor-
rect determination of the aforementioned quantitative param-
eters – it is essential that the concentration of activity in re-
spective lesions, volumes and sub-volumes (Bq/cm3) be de-
termined as accurately as possible. Therefore, the attenuation
and scatter of the 511 keV photons, until they reach the detec-
tor system, need to be involved in the reconstruction of the
emission data set. Attenuation of photons is mainly deter-
mined by the electron density of the material they travel
trough and interact with. With CT this electron density can
be directly obtained by using the CT transmission volume data
set after a (bi-linear) calibration of the linear attenuation coef-
ficients. In the case of PET/MR, the attenuation correction
(AC) is derived from a dedicated MR-AC protocol. In most
cases the obtained MR image is first segmented into two or
three tissue classes. The segmented tissue classes are assigned
a constant linear attenuation coefficient and the so-constituted
segmented μ-map is used for attenuation correction of the
emission data. Despite extensive research in this field, these
algorithms suffer from being insufficient to detect bone and
air. Moreover, often the lungs are assumed to be uniform and
not all air pockets (nasal cavities) are properly segmented. In
their recent implementations most of the vendors use
ultrashort- and zero echo time MR sequences to detect bone
(in certain body areas, e.g. the head) and, thus, improve the
performance of the tissue class segmentation [15, 16]. These
methods are combined with methods of μ-map generation
from MR data that use structural (i.e. T1- or T2 weighed)
MR data sets in combination with CT-atlas based information
of a particular part of the body to generate a more realistic map
of linear attenuation coefficients, including bone [17–21]. In
recent research settings, neuronal network approaches are
employed to train algorithms using real CT data to learn,
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generating continued valued maps of LACs on the basis of
structural MR data sets. Using these methods and depending
on the body compartment, the accuracy of the PET measure-
ment in hybrid PET/MRI settings now reaches the order of
accuracy of that in PET/CT settings. Yet, in particular cases
(pediatric, metal implants, ports, etc.) inaccurate attenuation
maps may still occur. All the hardware in the path of the
gamma rays needs to be taken into account, as it also attenu-
ates the PET signal. The (flexible or rigid) MR signal receiver
coils and the patient table are either implemented by CT-
measured maps of LACs or designed in a way that the atten-
uation of the PET signal by this material is negligible. Most of
the harmonization procedures of quantitative PET, as known
from PET/CT, are based on the measurement of known phan-
tom structures filled with watery solutions of radioactivity
containing different fillable sub-volumes and, thereby,
representing known activity concentrations in volumes of dif-
ferent sizes in an either cold or hot background. Firstly, being
constructed mainly of plastic, the structure of those phan-
toms cannot be detected sufficiently by MRI. Secondly,
large volumes of water in the MRI field of view cause
major distortions of the MR signal. This topic has been
addressed by searching for alternative liquids to fill the
phantom [22]. Current approaches to use activity fillable
phantoms in hybrid PET/MRI, however, employs the im-
plementation of CT-generated μ-maps of the particular
phantom to account for the attenuation of the PET signal.
Thus, inter-system quantitative comparisons give just the
comparability of the quantitative performance of the PET
detector systems. If the clinical settings for attenuation
correction – i.e. the MR-based μ-map – is used for atten-
uation correction of phantom measurements, consider-
able deviations of accuracy of the PET measurement
are found [23, 24].
The latest generation of hybrid PET/MRI systems is capa-
ble of Time Of Flight (TOF) PET signal detection [14]. This
information can be used for simultaneous reconstruction of
activity and attenuation [25, 26], which might enable further
improvement in the quantitative accuracy of PET/MR studies
and/or the mitigation of MR-AC related PET image artifacts.
There are several clinical implications arising from the
differences in PET-quantification between PET/CT and
PET/MR. Generally it is known that there is an underesti-
mation based on the above described Dixon-based attenu-
ation method. This underestimation is especially evident
close to bone [27]. Diagnostically the problem here is that
detection of lesions in or close to a bony structure can be
impaired. This naturally leads to possible underestimation
of the disease extent, especially in oncological diseases
with preference to bone metastases (e.g. breast cancer,
prostate cancer ,etc.) and thus inadequate therapy
decisions.
Moreover, comparability between follow-up studies in
PET/MR can be difficult, not only on the same system but
also when considering different PET/MR systems [23].
After therapy, glucose-utilization of tumorous lesions usu-
ally decreases, thereby indicating therapy response, even in
cases where the lesion’s size does not fulfill the criteria of
partial response. However, in cases of incorrect underesti-
mation of a lesion’s FDG-uptake, lesions might appear as
no longer having elevated uptake, whereas they in fact are
still FDG-avid. Here again, consecutive therapy misclassi-
fication cannot be excluded in such cases.
This problem is even more aggravated in follow-up
studies between PET/CT and PET/MR based on this
SUV-underestimation. A technical compensation for this
issue might be that both available PET-components in
simultaneous systems have a higher sensitivity, which
might partially compensate for the diagnostic loss.
However, there is currently no study available which
investigates this systematically.
In those cases of incorrect underestimation, diffusion
weighted imaging from the MR-component, for example,
might be of help diagnostically. However, MR-sequences
Fig. 1 Number of articles reporting the use of MATV, SUVmax and
SUVpeak as a function of year of publication. Articles were identified by
Medline search with the following keywords: (MTV OR MATV AND
PET), (SUVmax ANDPET) or (SUVpeak AND PET). Only human studies
were included
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are usually even less standardized between different institu-
tions than PET-systems.
Summary of causes and magnitude of errors in SUV
measurements
The causes and the magnitudes of errors in SUV measure-
ments have been described in detail elsewhere [28]. These
errors can be classified into three categories and are briefly
summarized in Fig. 2. It is worth mentioning that among the
technical causes of errors in SUV calculation, reconstruction
variability has taken a prominent place over the last decade,
with technological improvements in PET technology having a
huge impact on SUVmeasurements. For example, reconstruc-
tions including the PET/CT system resolution model (so-
called PSF reconstruction), with no post-filtering, have been
reported to increase SUVmax beyond 66% in small nodal me-
tastases in breast cancer [29], or for NSCLC as reported by
Kuhnert et al. The increase in PET quantitative metrics due to
this algorithm will depend on the post filtering settings, but
PSF reconstructions are usually used with little to no filtering.
More recently, Bayesian penalized likelihood (BPL)
Fig. 2 Illustration of
reconstruction harmonization
methods and brief summary of the
main factors influencing SUV
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reconstruction has been shown to improve tumor detection
and to increase SUV metrics [30, 31]. A review of recent
advancements in PET technology can be found elsewhere in
this supplement [32].
The issue of reconstruction variability among PETcenters
In an international survey, Beyer et al. [33] reported that 52%
of sites used alternative protocols with adapted reconstruction
parameters. Of note, there is a reconstruction variability even
between centers running similar systems: Sunderland et al.
[34], from the SNMMI clinical trials network, reported that
site-specific reconstruction parameters increased the quantita-
tive variability among similar scanners, with post-
reconstruction smoothing filters being the most influential pa-
rameter. In their survey involving 237 PET/CTsystems in 170
international imaging centers, with technology advancements
spanning more than a decade and covering the three major
PET manufacturers (GE Healthcare, Siemens and Phillips
Healthcare made up approximately 56%, 34% and 10%),
more than 100 reconstruction parameters were reported.
Rausch et al. [35] reported an overview of clinical PET/CT
operations in Austria in a survey involving 12 PET centers
(GE Healthcare, Phillips Healthcare and Siemens Healthcare
made up 4/12, 7/12 and 2/12, respectively). Graham et al. [36]
reported a survey in 15 US centers. Table 1 summarizes data
available from these surveys. As can be seen in Table 1, all
these reports suggest a huge variability in state of the art PET/
CT system performance in the absence of a careful PET/CT
system harmonization program.
Harmonization strategies
From preparation of patient in the PETunit to acquisition
and reconstruction
(EARL, UPICT)
A detailed review of various factors affecting SUV (and
MATV, TLG) can be found in [28, 37, 38]. When a patient
undergoes a PET/CT examination, errors may occur during
the entire process of the study. During this process several
steps can be identified, such as: (1) patient instruction, at least
one day prior to the examination to ensure, e.g., that patient
has fasted properly; (2) patient preparation and FDG admin-
istration; (3) PET/CT examination; (4) Image reconstruction/
generation; (5) Image analysis and interpretation. A detailed
overview of the various steps is summarized in the UPICT
protocol and EANM version 2.0 guidelines [4, 39]. In all steps
of the examination it is essential to mitigate the sources of
errors [28]. From an image acquisition and reconstruction
point, it is important to ensure that the PET/CT examination Ta
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is of sufficient quality. The latter depends on (the combination
of) patient weight, scan duration, FDG activity administered,
PET/CT system sensitivity and image reconstruction methods
and settings. To ensure sufficient image quality and harmo-
nized image quantification, the EANM guideline gives specif-
ic recommendations for the (minimal) FDG activity to be ad-
ministered in relation to patient weight and image acquisition
parameters.Moreover, based on this guideline a PET/CT qual-
ity control program was launched in 2010 aiming at harmo-
nizing image quality and quantification across sites and PET/
CT systems. For SUV bias and recovery coefficients, EARL
accreditation acceptance limits were established based on the
results of a feasibility study performed on PET/CT systems
currently used in clinical practice, including different types
from different vendors. The specific aim of this EARL accred-
itation program is to ensure exchangeability or pooling of
quantitative results in a multicenter setting, although the au-
thors suggested that it is also beneficial to derive interpretation
criteria for routine clinical use of quantitative PET/CTmetrics.
The EARL program uses a specific set of quality control
(QC) experiments. The first one aims to verify the basic cali-
bration of the PET/CT relative to the dose calibrator used to
measure the patient FDG activities. The experiment uses a
simple uniform phantom; it is designed to ensure consistent
calibrations between these two devices and thereby correct
SUV calculations. This QC is required by EARL quarterly
to verify that the accurate calibration of the accredited PET/
CT system is ensured over time on site. The second QC re-
quires the NEMANU 2 image quality phantom and is used to
derive the reconstruction settings that results in comparable
SUVs across systems by harmonizing SUV recoveries. The
EARL program provides harmonizing specifications for SUV
recoveries, i.e. both lower and upper limits are provided,
thereby aiming at minimizing differences in quantitative reads
between sites, systems and reconstruction methods. This sec-
ond QC is repeated annually and/or after major repairs of the
PET/CT system.
The EARL accredited department pledges itself to perform
all FDG PET/CT oncology examinations, at least all quantita-
tive ones, strictly as described in the EANM guideline (up-
dated version), to provide a minimum standard for the acqui-
sition and interpretation of PET/CT scans, using the EARL
approved parameters.
While most of the causes of errors in PET quantitative
measurements can be overcome by complying with existing
guidelines, from preparation of the patients to acquisition, a
specific issue is related to reconstruction-dependent variations
encountered with recently introduced advanced image recon-
struction algorithms, such as those incorporating the point
spread function (PSF) [40], or BPL reconstruction [31].
These new image reconstruction schemes have been shown
to produce SUVmetrics significantly higher than convention-
al ordered subset expectation maximization (OSEM)
algorithms [29]. Consequently, an additional filtering step
has to be used in order to meet harmonizing standards [4,
41, 42]. In this way the benefits of PSF reconstruction for
visual interpretation can be combined with compliance to in-
ternational quantitative harmonizing standards, as will be
discussed below.
Clinical validation of the EARL harmonization strategy
Given that centers running PETsystems with advanced recon-
struction algorithms are often willing to use them as such in
order to achieve optimal tumor detection, EARL-accredited
centers tend to use two PET datasets: one for optimal lesion
detection and image interpretation, and a second (possibly
filtered) one for harmonized quantification [41]. This strategy
has been validated in several studies that mimicked a situation
in which a patient would undergo pre- and post-therapy PET
scans on different generation PET systems by comparing
SUVs for an OSEM reconstruction known to meet the
EANM harmonizing standards to a PSF or PSF + TOF recon-
struction optimized for diagnostic purposes and then SUVs for
a PSF or PSF + TOF EARL-compliant reconstruction.
In a series of 52 NSCLC with 195 lesions [41], Bland-
Altman analysis demonstrated that the mean ratio between
PSFall pass and OSEM data was 1.48 (95% CI 1.06–1.91)
and 1.37 (95% CI 0.89–1.85) for SUVmax and SUVmean, re-
spectively. After having applied the appropriate filter, the
mean ratios between PSFEARL and OSEM data were 1.03
(95% CI 0.94–1.12) and 1.02 (95% CI 0.90–1.14) for
SUVmax and SUVmean, respectively. Since no confounding
factors (tumor size, intensity, and location) were found, this
methodology could be used in any type of solid tumors.
Second reconstruction versus software technology
To avoid the reconstruction of two datasets, a proprietary soft-
ware solution, marketed as EQ.PET (Siemens, Oxford, UK),
has been developed to simultaneously allow optimal lesion
detection and harmonized quantification from a single dataset
[42, 43]. This software simultaneously presents the recon-
struction that provides optimal lesion detection for diagnostic
interpretation with harmonized SUV results. EQ.PET is a pat-
ented automatic software systemworking Bbehind the scenes^
without possibility for the imaging specialist to check the ad-
equacy of region of interest placement. Both EARL harmoni-
zation strategy and EQ.PETsoftware operations are illustrated
in Fig. 2.
EQ PET has been validated in a series of 517 patients with
NSCLC, non-Hodgkin lymphoma and metastatic melanomas
[44]. In this prospective multicentre study, 1380 tumor lesions
were studied and Bland-Altman analysis showed a mean ratio
between PSF or PSF + TOF and OSEM of 1.46 (95%CI:
0.86–2.06) and 1.23 (95%CI: 0.95–1.51) for SUVmax and
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SUVpeak, respectively. Application of the harmonizing soft-
ware improved these ratios to 1.02 (95%CI: 0.88–1.16) and
1.04 (95%CI: 0.92–1.17) for SUVmax and SUVpeak, respec-
tively. It is noteworthy that in this study, two centers used
similar PET equipment but different reconstruction parame-
ters: one used PSF modeling and no post filtering, while the
other used Gaussian filtering with a kernel depending on the
patients’ body habitus. This well reflects the issue of recon-
struction variability pointed out by several European and US
surveys and described above.
Lasnon et al. [45] compared the EQ.PET methodology
(PSFEQ) with the use of a second harmonized reconstruction
(PSFEARL) in a series of 55 NSCLC cancer patients (171 le-
sions) imaged on a system equipped with PSF modeling and
showed that the mean PSFEARL/PSFEQ ratio for SUVmax and
SUVpeak were 1.01 (95%CI: 0.96–1.06) and 1.01 (95%CI:
0.97–1.04), respectively.
Therefore reconstruction-dependency in SUVs can be
overcome by using two reconstructions for harmonized quan-
tification, and optimal diagnosis and could be managed by
using software approaches like the EQ.PET technology, pro-
vided it is widely available and vendor neutral. Both technol-
ogies produce similar results, the software solution sparing
reconstruction and interpretation time.
Harmonization and liver-based scales
The Deauville score (DS) compares FDG uptake in the resid-
ual masses with that in the mediastinal blood pool and in the
liver, following chemotherapy in Hodgkin lymphomas (HL)
and non-Hodgkin lymphomas (NHL) [46]. DS is widely used
from interim and end-treatment PET. In order to better char-
acterize non-responding disease (i.e uptake slightly superior
or greatly superior to liver background, defined as DS 4 and
DS 5, respectively), it has been suggested to compute lesion/
liver ratio and to use a 1.3 cutoff value.
Based on the SUV formulae described above, one could
assume that the use of a ratio would allow one to remove the
reconstruction variability, the hypothesis being that an over-
estimation due to the use of an advanced reconstruction algo-
rithm would equally impact the lesion and the liver SUVs. In a
series of 23 NHL patients with a total of 388 lesions [47], PSF
reconstruction was shown to increase the tumor-to-liver ratio
by 31% (ratio 1.31, 95% CI: 0.79–1.82) compared to the con-
ventional OSEM algorithm. After having applied a Gaussian
filter chosen to meet the EANM harmonizing standards
(PSFEARL), the ratio of the tumor- to-liver ratio for PSFEARL
and OSEM was found to be 1.06 (95% CI:0.93–1.18), with a
narrow 95% confidence interval. Therefore, the lesion/liver
ratio, if used as a discriminator between a positive and nega-
tive exam in NHL patients, is PET system and image recon-
struction method dependent, and harmonization is thus still
warranted. This is in line with a study from Kuhnert et al.
[48], in which SUVs were compared in PSF + TOF recon-
struction versus OSEM in a series of 40 lung cancer patients.
Their study demonstrated that SUVs were constantly in-
creased in PSF + TOF images, despite normalization to the
liver. On average, the observed increase was 60% and 30% for
SUVmax and SUVpeak, respectively. These values can be com-
pared to those observed by Lasnon et al. [41] using PSF
modeling with no filtering and described in detail above.
Taken together, these data show that harmonization is war-
ranted not only for SUV metrics, but also for tumor/liver ra-
tios, which is of importance in the context of ongoing efforts
to better stratify lymphoma patients with persistent disease, as
discussed during the recentMenton congresses on Lymphoma
and pointed out in the review by Barrington et al. [49].
Harmonization and therapy assessment with EORTC
response criteria and PERCIST
Various schema based on the degree of SUV change after
treatment have been proposed in an effort to bring consistency
to the classification of responses across trials, emulating the
use of the RECIST for CT. A 25% threshold in SUVmax var-
iation and a 30% variation in SUVpeak are used to discriminate
between responding and non-responding tumors [50]. The
EORTC criteria and PERCIST can be used not only for trials
but also in daily routine.
As shown in Fig.3, reconstruction variability can lead to
overestimation of SUVmax and SUVpeak, exceeding the thresh-
olds used to discriminate between responding (partial meta-
bolic response) and non-responding (stable or progressive
metabolic disease) patients. Also noticeable is the greater sen-
sitivity of SUVmax to reconstruction variability, compared to
SUVpeak. Conversely, one could expect PERCIST to be less
sensitive than EORTC criteria to reconstruction inconsis-
tencies between pre- and post-treatment scans.
The impact of reconstruction inconsistency on therapy as-
sessment was investigated in two studies: a prospective
multicentre study involving 86 patients with NSCLC, colorec-
tal liver metastases and melanoma metastases focused on
PERCIST [51], and a single-centre series of 61 NSCLC spe-
cifically addressing the issue of the relative sensitivity of
EORCT criteria and PERCIST to reconstruction variability
[52]. In both studies, the use of a conventional OSEM algo-
rithm for the pre- and post-treatment scans was used as the
standard of reference (OSEMPET1/OSEMPET2 scenario).
For the OSEMPET1/OSEMPET2 scenario, the change in
SULpeak was −63.9 ± 22.4 and +60.7 ± 19.7 in the groups of
tumors showing a decrease and an increase in FDG uptake,
respectively, while the change in SULmax was −57.5 ± 23.4
and +63.4 ± 26.4 in the groups of tumors showing a de-
crease and an increase in 18F–FDG uptake, respectively.
The use of PSF or PSF + TOF reconstruction affected tumor
classication, depending on whether this reconstruction was
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used for the pre- or post-treatment scans. For example, tak-
ing the OSEMPET1/PSF or PSF + TOFPET2 scenario (a situ-
ation that would be faced if a system upgrade were done
during a trial), would decrease the apparent reduction in
responding tumors and would increase the percentage change
in progressing tumors. Conversely, this was shown to affect
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both the EORTC and PERCIST classifications. In agreement
with the higher reconstruction-dependency of SUVmax compared
to SUVpeak, the discordances between scenarios involving recon-
struction inconsistencies and the standard of reference
(OSEMPET1/OSEMPET2 scenario) were more frequent for
SUVmax/EORTC. Of note, the potential impact of these discor-
dances was more important for the EORTC compared to
PERCIST, more patients’ classifications being changed from re-
sponder [partial metabolic response (PMR) or complete metabol-
ic response (CMR)] to non-responder [stable metabolic disease
(SMD) or progressive metabolic disease ( PMD)]. After having
applied an appropriate filter to comply with the EANM harmo-
nizing standards, agreement levels between the OSEMPET1/
OSEMPET2 scenario and other scenarios involving reconstruction
inconsistency were found to be almost perfect, with narrow con-
fidence intervals. Figure 3 displays the percentage changes for
the different scenarios and PERCIST or EORTC classifications.
Of note, PERCIST recommend using the lesion harboring the
highest FDGuptake as a target lesion and do not require the same
target lesion to be used on pre- and post-treatment scans. In that
setting, given that new reconstruction algorithms have been
shown to improve lesion detectability, a different target lesion
could be chosen on OSEM and PSF images. In the study from
Quak et al. [52], a change in selected PERCIST target lesion
occurred in only 3 of 172 scans (2%). Also, among patients
classified as PMD because of the appearance of new lesions,
OSEM and PSF or PSF + TOF performed equally in detecting
these new lesions, despite the potential for PSF reconstruction to
detect smaller cancer lesions compared with OSEM
reconstruction.
Harmonization and MATV
Because twoMATVs of a given tumor could, in theory, not be
identical, i.e. representing different metabolic parts of the tu-
mor, validation of the EARL harmonization strategy requires
that MATV are compared not only in terms of absolute and
relative values, but also using a representative geometrical
description of MATV changes, combining volume and posi-
tional changes. In that setting, Dice’s and concordance indices
are frequently used. Their values vary between 0 if the
MATVs are completely disjointed and 1 if the MATVs match
perfectly in terms of size, shape and location.
Using the 40% isocontour method and taking MATV delin-
eated on OSEM images as a reference standard, Lasnon et al.
[53] showed in 18 NSCLC patients that the use of EARL-
compliant images led to significantly higher Dice’s coefficients
(median value = 0.96 vs 0.77, P < 0.0001) and concordances
indices (median value = 0.92 vs 0.64, P < 0.0001), compared to
the use of PSF images optimized of diagnostic. This shows that
automatically contouring tumors on EARL-compliant PSF im-
ages with the widely adopted automatic isocontour methodol-
ogy is an accurate means of getting rid of reconstruction vari-
ability in MATV delineation.
Using PET EARL-compliant images to evaluate tumor
heterogeneity
Heterogeneity metrics are emergent and alternative PET mea-
surements [54–57]. The most promising approach for heteroge-
neity quantification is textural features (TF) analysis. Recently,
the impact of reconstructions on TF values has been highlighted
and the efficacy of harmonization programs initially developed
for standard SUV metrics has been tested: in a series of 60
NSCLC patients, several 18F–FDG heterogeneity metrics were
compared in PSF, PSF-filtered (EARL-compliant) and OSEM
reconstructed images. Tested TF were CHAUC (first-or-
der metric); entropy, dissimilarity and correlation (sec-
ond-order metrics); ZP and HILAE (third-order metrics).
When using the same volume of interest (VOI) on the three
reconstructions (thus avoiding a VOI-related bias), Lasnon
et al. [58] found significant differences between OSEM and
PSF images for all heterogeneity metrics except for entropy
and ZP; the latter could therefore be used in the case of
multicentre studies within centers using different reconstruc-
tion settings. When comparing heterogeneity metrics extract-
ed from OSEM and PSF7 images, none exhibited significant
differences, emphasizing that the quantifiable heterogeneity
contents of PSF7 images are very close to those in OSEM
images whatever the MATV considered, and supporting the
use of harmonization strategies in multicentre studies using
TF as biomarkers. However, it is noteworthy that overall,
PSF images displayed higher heterogeneity and higher ranges
of heterogeneity, especially when analyzing the largest tumors
(>1cm3). This suggests that PSF-reconstructed images could
be more accurate in discriminating different levels of intra-
tumoural heterogeneity than OSEM-reconstructed images,
and that when available, PSF-images should be exploited in
addition to EARL-compliant images.
Fig. 3 Effect of reconstruction inconsistencies and impact of
harmonization on therapy assessment with EORTC response criteria
and PERCIST. Relationship between standardized uptake values
normalized to lean body mass (SUL)max and SULpeak in lesions
extracted from PSF ± TOF (a) or PSF ± TOF.EQ (b) and OSEM
images, assessed using Bland-Altman plots. Of note is the greater
sensitivity of SUVmax to reconstruction variability, compared to
SUVpeak: the number of cases exceeding the threshold to discriminate
between SMD and PMD, due to reconstruction inconsistency, is higher
for SUVmax. Conversely, PERCIST appears less sensitive than EORTC
criteria to reconstruction inconsistency between pre- and post-treatment
scans: panel c displays EORTC classification and PERCIST for the
standard of reference (OSEMPET1/OSEMPET2) and for other scenarios.
d: representative images of a 72-year-old male patient with NSCLC
treated by chemotherapy, classified as SMD according to the standard
of reference. The use of OSEM for baseline scan and PSF + TOF for
post-treatment scan, mimicking a system upgrade during a trial, would
lead to PMD classification for both EORTC and PERCIST, while the use
of harmonized data would correctly classify the patient
Eur J Nucl Med Mol Imaging (2017) 44 (Suppl 1):S17–S31 S25
Implementing the EARL strategy in daily practice
andmulticentre studies: Results from the EARL electronic
survey (Fig. 4)
An electronic survey took place over a two-week period in
September 2016 among EARL-accredited centers. At the time
of this survey, 169 centers were accredited. The link to this
online survey was sent to the referring physician or physicist
of each centre. One reminder was sent 48H before the closure
of the survey; 115 centers viewed the questionnaire and 51
centers responded, meaning a response rate of 44%.
Most of the centers that responded to the survey are centers
performing more than 15 PET examinations per day and par-
ticipating in clinical trials. Half of these centers reported the
implementation of the EARL accreditation program as easy.
With regards to daily practice, most of the centers use a
reconstruction optimized for diagnostic images in addition to
the use of EARL compliant images, half of them using three
reconstructions for a standard oncological PET scan (i.e. im-
ages optimized for diagnostic, corrected and uncorrected for
attenuation + EARL-compliant images, the latter being sys-
tematically used for quantification in 38% of centers and only
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Fig. 4 Results from the EARL electronic survey. Data are displayed as pie charts
for clinical trials in a third of the centers). Given the increasing
number of PET centers running more than one PET system,
the systematic use of EARL images is likely to increase, as
always scanning a patient on the same PETscanner is difficult.
In line with the number of reconstructions being used in
EARL-accredited centers, most of the centers reported the
lack of impact of the EARL program on the throughput of
their unit. When it comes to clinical trials, the impact of the
EARL program was judged positive in half of the cases, but a
third of the centers reported that paperwork is still needed.
Future evolutions and imaging guideline updates
Weight measurement: A neglected cause of variability?
In a survey involving 513 consecutive patients in an
EARL-accredited centre, Lasnon et al. [59] showed that,
compared to the actual weight, using weight reported on
the PET request forms led to an overestimation and an
underestimation greater than 10% in 35 (7.4%) and 23
(4.9%) patients, respectively. Based on the SUV formu-
lae, an overestimation of patient’s weight can lead to an
overestimation of SUV metrics, and vice versa. These
errors may hamper efforts to meet quantitative harmo-
nizing standards. Based on this survey, two strategies
can be proposed: either to systematically ask patients
to weigh themselves 48 h before the PET examination
when they are called-up, or, especially in other PET
units where patients are not systematically called-up,
to weigh patients upon their arrival in the PET unit on
a calibrated weighing scale. This last option could be
easily generalized to all patients, (i.e. not only those
imaged within clinical trials, as suggested by the
UPICT protocol [39] but also those being scanned in
clinical routine).
Lean body mass (LBM) versus weight for SUV
calculation: How to evaluate LBM
PERCIST [60] recommend the use of SUV normalized by
lean body mass (SUVLBM) rather than SUV normalized by
body weight (SUVBW). Indeed, SUVLBM has been shown to
be more consistent by taking into account that adipose tissue,
the amount of which is highly variable among patients, does
not significantly accumulate FDG. Regarding SUV definition,
this theoretically leads to an underestimation of SUVBW in
obese patients. There are two main methods of LBM calcu-
lation: indirect estimation by predictive equations (PEs)
and direct determination by using computed tomography
(CT).
Modern PET/CT systems use PEs based on basic anthro-
pometric parameters (gender, body weight, height ± age). For
example, one of the most common, called the James equation,
is defined as follows:
LBM James ¼ 1:1 BW−128 BWHeight
 2
for men
LBM James ¼ 1:07 BW−148 BWHeight
 2
for women
However, these equations have some limitations that ham-
per their reliability. It has been shown that most of the PEs
were significantly different from LBM derived from dual-
energy x-ray absorptiometry, which is one of the most accu-
rate reference methods, with wide variations in LBM estima-
tion [61]. It is noticeable that this study included some PEs
previously used to normalize SUV. Moreover, Tahari et al.
demonstrated inappropriately low hepatic level SUL values
in female and male obese patients when using the James equa-
tion described above [3]. Therefore, instead of estimation, an
individual LBM measurement seems to be more reliable.
As all patients now have a systematic CTscan coupled with
their PET acquisitions, some have proposed using this source
of information to directly determine LBM based on
Hounsfield densities. The fat peak is well defined on CT his-
togram (from −190 to −30 HU) and depends little on the
image noise, so no CT parameter adaption is required [62].
For the great majority of patients, the field of view (FOV)
covers only skull to mid-thighs, but several studies have dem-
onstrated that the estimation of LBM on a limited FOV has an
excellent agreement with the LBMmeasured on a whole-body
CT [1]. When comparing PEs and CT LBM determinations,
substantial errors were found between SUL calculated with
PEs compared to CT, with errors in individual SUL values
ranging from 25% to 51% [63].
Obesity being a progressing disease, SUL determination
improvements must be a matter of major concern, as it is an
important endpoint in the outcome of oncologic patients.
New harmonization initiatives
New isotopes
The current EARL program was developed to harmonize
PET/CT system performance for multicenter FDG PET/CT
studies. Although the focus was on FDG and quality control
experiments for obtaining accreditation use 18F(FDG) as a
radioisotope, the program is applicable to any other 18F la-
beled radiopharmaceutical. New EARL initiatives are under-
way to address the use of other radioisotopes, such as 89Zr [64]
and 68Ga. In most cases the EARL approved acquisition and
reconstruction parameters (for FDG) may be applied directly
to obtain harmonized PET/CT performance for these other
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isotopes. However, when using isotopes other than 18F, sever-
al isotope dependent issues need to be considered. First of all,
the positron range may be substantially longer than that of 18F,
which is, in particular, the case for both 89Zr and 68Ga. The
longer positron range results in lower SUVor contrast recov-
eries for smaller objects (<1.5 cm diameter). Yet, the effects of
positron range on observed contrast recovery should be the
same, regardless PET/CTsystems used. A pragmatic approach
for harmonizing PET/CT systems for 89Zr and 68Ga would be
to simply use the 18F(FDG) approved settings, thereby
avoiding the need to install multiple isotope specific EARL
protocols on the PET/CTsystem, and to validate only 89Zr and
68Ga recoveries under these conditions. Secondly, a proper
cross-validation of PET/CT calibration with that of the dose
calibrator used to determine the patient activities is still war-
ranted. The latter is sometimes hampered by the lack of the
appropriate isotope information on either the PET/CT system
or dose calibrator. Use of incorrect isotope settings will result
in incorrect decay correction and use of the wrong positron
abundance. Both issues will result in incorrect measurement
of the activity concentrations or activities by the systems,
which is unacceptable for clinical use. Therefore, EARL will
set up these new programs in order to facilitate the use of these
potentially interesting and widely used new isotopes in multi-
center studies.
New PET technologies
Of importance to note is that EARL is a multicenter standard
aiming at harmonizing PET/CT systems regardless of their
technological capabilities. The standards were set to achieve
the highest common denominator for state of the art PET/CT
systems. PET-only systems were not used to derive the stan-
dards and the standards were not defined by the worst
performing systems. Yet, given the recent developments in
PET technologies, such as the introduction of PSF reconstruc-
tions and digital PET detectors, the EARL standard may need
to be updated. It should be noted, however, that a substantial
fraction of the PET/CT systems in Europe still does not have
PSF reconstruction capabilities, let alone digital PET detec-
tors. Update of EARL is inevitable, but its implementation
depends on the installed base of PET/CT systems in Europe
and the support of vendors to accommodate new EARL stan-
dards. At present, efforts supported by EARL and the
Quantitative Imaging Biomarkers Alliance (QIBA) [65] are
undertaking to obtain a new set of experiments to test the
feasibility of harmonizing PET/CT systems with PSF recon-
structions, possibly in combination with use of SUVpeak, and
even digital PET detectors, but data are still preliminary. Once
a new standard has been implemented its impact on quantita-
tive PET results and (quantitative) PET interpretations should
be addressed. It can be expected that by using a standard that
facilitates the use of new PET technologies, SUVs will be
higher and MATVs smaller. The translation of interpretation
criteria from an old to a new standard could be addressed
either by performing multiple reconstructions or by use of a
post reconstruction filter, i.e. the same strategies currently
followed by most sites to obtain images optimized for visual
interpretation and for multicenter quantification. Although the
latter is a challenge, the transition from one standard to anoth-
er is more preferable than the use of quantitative PET in an
unstandardized chaotic manner, as the surveys of Sunderland
et al. and Graham et al. have revealed [34, 36].
Harmonization for PET/MR devices
Combined or integrated PET/MR was introduced several
years ago and has gained increased interest, although mainly
in the academic world, in exploring its capabilities and use. In
most PET/MR systems the PET component performs similar-
ly to its PET/CT counterparts, although some lack the use of
time of flight, while other systems already use digital PET
technologies. Despite these technical differences, the ap-
proach to harmonizing the PET performance is not different
from that of PET/CT systems. A particular challenge for PET/
MR is the lack of PET phantoms that are commonly used for
the calibration and quality control of PET/CT systems. But
Boellaard et al. [24] recently showed that all PET/MR systems
have implemented protocols and image reconstruction
methods that allow the use of uniform cylinders to calibrate
the PET(/MR) system as well as the use of the NEMA Image
Quality phantom to perform NEMA and/or EARL Image
Quality QC experiments. In this way the current EARL ac-
creditation program for PET/CT can be applied PET/MR sys-
tems as well. Although the latter assures harmonized perfor-
mance of the PET component of the PET/MR from a physics
or technical perspective, quantification in humans may still be
hampered by limitations in the commercially provided solu-
tions for MR based attenuation correction. An overview of the
various issues related to quantitative PET/MR imaging can be
found in [66]. Moreover, it has also been shown that the com-
mercially provided MR based attenuation correction methods
may suffer from poor repeatability and reproducibility (be-
tween systems) as shown by Beyer et al. [23]. Yet, as
discussed earlier, more advanced and accurate MR based at-
tenuation correction methods have been developed; when
these new methods are employed the quantitative accuracy
of PET/MR will be equivalent to that of PET/CT for most
cases, but validation and inspection of the attenuation correc-
tion maps remains warranted.
Conclusions and perspectives
Use of quantitative PET/CT parameters, such as SUVs or
MATVs, as imaging biomarkers in multicentre trials or in sites
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equipped with multiple scanners requires that these parame-
ters be comparable among patients, regardless of the PET/CT
system used. The EANM/EARL program, one of the interna-
tional harmonization programs aiming at using FDG PET as a
quantitative imaging biomarker in clinical trials, requires a
specific set of quality control experiments, including a set of
PET images with NEMA NU-2 anthropomorphic phantom-
based filtering to harmonize SUVs to the EANM standards.
EARL-accredited centers tend to use two PET datasets: one
for optimal lesion detection and image interpretation, and a
filtered one for harmonized quantification. In this way the
benefits of advanced reconstruction algorithms such as PSF
or PSF + TOF for visual interpretation can be combined with
compliance to international quantitative harmonizing stan-
dards. The EARL accreditation program has been proven to
be effective in getting harmonized quantitative values, in par-
ticular by overcoming algorithm and reconstruction variability
across PET systems. Its clinical validation was made in a wide
range of tumor types, not only for SUV metrics, but also for
MATV and heterogeneity features. The need for harmoniza-
tion in therapy assessment and the efficiency of the EARL
program in this setting have been demonstrated for both the
EORTC response criteria and PERCIST. A recent survey
across EARL accredited sites suggests that EARL accredita-
tion and use of EARL accredited protocols, either by them-
selves or in combination with locally preferred settings opti-
mized for lesion detection, do not hamper clinical routine and
throughput.
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